Oncology
6 drugs are in development for Pancreatic Ductal Adenocarcinoma (PDAC).
- Companies
- 6
- Clinical trials
- 23
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Pancreatic Ductal Adenocarcinoma (PDAC) pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(3)
| Drug | Company |
|---|---|
| atebimetinib | Immuneering Corp (IMRX) |
| batiraxcept | Aravive, Inc. (ARAV) |
| daraxonrasib | REVOLUTION MEDICINES, INC. (RVMD) |
Phase 1(2)
| Drug | Company |
|---|---|
| darlifarnib | Kura Oncology, Inc. (KURA) |
| STRO-004 | SUTRO BIOPHARMA, INC. (STRO) |
Preclinical(1)
| Drug | Company |
|---|---|
| neo-stc-01 | Neon Therapeutics, Inc. (NTGN) |
About this indication
Pancreatic Ductal Adenocarcinoma (PDAC) context
Oncology·MeSH: Pancreatic Neoplasms (D010190)
Narrower concept of MeSH descriptor Pancreatic Neoplasms
Prevalence
7.1 / 100K
Incidence
7.5 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Pancreatic Ductal Adenocarcinoma (PDAC)?
BioSniper tracks 6 drugs in development for Pancreatic Ductal Adenocarcinoma (PDAC) across 6 companies.
How many clinical trials target Pancreatic Ductal Adenocarcinoma (PDAC)?
There are 23 clinical trials targeting Pancreatic Ductal Adenocarcinoma (PDAC) tracked by BioSniper.
What is the prevalence of Pancreatic Ductal Adenocarcinoma (PDAC)?
The estimated prevalence of Pancreatic Ductal Adenocarcinoma (PDAC) is approximately 7.1 per 100,000 population.